T3D Therapeutics Closes $15M Financing to Advance Phase 2 Development of T3D-959 in a New Approach to Treating Alzheimer’s Disease.

T3D Therapeutics is now fully funded to initiate the Phase 2 PIONEER Study of T3D-959 in Mild-to-Moderate Alzheimer’s Disease Patients RESEARCH TRIANGLE PARK, N.C., Nov. 4, 2019 — T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced today that it has closed on a $15 million financing from a cornerstone investor. These funds, along with support from the National Institute on Aging (NIA), part of NIH, completes the funding needed to begin the PIONEER Study of T3D-959, a novel, metabolic-focused AD drug treatment. Read the Full Press Release Here

The release as fetched from its publisher. t3dtherapeutics.com ↗